ClinicalTrials.gg
CompletedNCT00927836AXIS-2Updated Dec 13, 2011

AXIS 2: AX200 for the Treatment of Ischemic Stroke

A Phase 2 interventional study of Filgrastim and Sodium chloride solution in Acute Ischemic Stroke, sponsored by Sygnis Bioscience GmbH & Co KG. Completed at 58 sites in 7 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2011-12-13.

Sponsored by Sygnis Bioscience GmbH & Co KG · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
328
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 164 studies in Ischemic Stroke with a site in Germany — 41 open to participants now, 50 under way, 5 of them phase 3. Ischemic Stroke · Germany.

Enrollment
43rd of 101
328 · median 223
Started
2009
with 8 others
Phase 2
28 of 164
3 open now
Registered
23rd of 164
by date

Among the 164 studies in Ischemic Stroke with a site in Germany, this one is the 43rd largest by enrollment of the 101 interventional ones that give a count, is one of 9 that started in 2009, is one of 28 in phase 2, and was the 23rd registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

41 of the 164 studies in Ischemic Stroke with a site in Germany are open now. Recruiting first, the newest first:

36 more — sign in →

All 41 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Ischemic Stroke with a site in Germany, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy of AX200 (filgrastim) in the treatment of acute ischemic stroke and to assess the safety and tolerability of AX200.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Major Inclusion Criteria:

  • diagnosis of acute ischemic stroke with an onset within 9 hours prior to start of study agent administration
  • ischemic stroke in the MCA territory confirmed by MRI (diffusion)
  • age ≥18 years and ≤85 years
  • lesion size on DWI ≥15 ccm
  • written

Major Exclusion Criteria:

  • prior to current stroke: inability to walk or to lead an independent life
  • less or equal 6 months
  • stupor or coma
  • lacunar infarct
  • any evidence of ICH
  • malignant hypertension
  • presence of history of active
  • count \<100/nl at randomization
  • leukocyte count >20/nl at randomization
  • congenital neutropenia
  • pregnant or lactating women
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
328 participants (actual)

Study arms

  • Experimental
    AX200

    Biological: Filgrastim

  • Placebo comparator
    Placebo

    Drug: Sodium chloride solution

Interventions

  • BiologicalFilgrastim

    135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days

  • DrugSodium chloride solution

    Short term infusion (20 to 30 minutes) and continuous infusion over 3 days

06

What researchers measure

Primary outcomes

  1. Improvement on mRS relative to placebo-treated patients

    Time frame: day 90

Secondary outcomes

  1. Improvement on NIHSS relative to placebo-treated patients

    Time frame: day 90

07

Study locations

58 sites
  • Landes-Nervenklinik Wagner-Jauregg
    Linz, 4020, Austria
  • AHK Linz
    Linz, 4021, Austria
  • Wilhelminenspital
    Wien, 1160, Austria
  • AZ Sint-Jan AV
    Brugge, 8000, Belgium
  • Cliniques Universitaires Saint-Luc
    Bruxelles, 1200, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • UZ Gasthuisberg
    Leuven, 3000, Belgium
  • St. Anne's Faculty Hospital
    Brno, 656 91, Czech Republic
  • Faculty Hospital
    Olomouc, 775 20, Czech Republic
  • Faculty Hospital Ostrava
    Ostrava, 708 52, Czech Republic
  • Municipal Hospital Ostrava
    Ostrava, 728 80, Czech Republic
  • Faculty Hospital 1
    Plzeň - Lochotín, 304 60, Czech Republic
  • General Faculty Hospital
    Praha, 120 00, Czech Republic
  • Faculty Hospital Motol
    Praha, 150 06, Czech Republic
  • Universitätsklinikum der RWTH Aachen
    Aachen, 52074, Germany
  • Kreiskrankenhaus Altenburg gGmbH
    Altenburg, 04600, Germany
  • Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Charite Universitätsklinikum "Benjamin Franklin" Klinik und Poliklinik für Neurologie
    Berlin, 12200, Germany
  • Evangelisches Krankenhaus Bielefeld
    Bielefeld, 33617, Germany
  • Klinikum Bremen-Mitte gGmbH
    Bremen, 28177, Germany
  • Klinik für Neurologie Chemnitz
    Chemnitz, 09131, Germany
  • Marienhospital Düsseldorf
    Düsseldorf, 40479, Germany
  • Universität Erlangen-Nürnberg
    Erlangen, 91054, Germany
  • Universitätsklinikum Essen
    Essen, 45122, Germany
  • Neurologische Universitätsklinik Freiburg
    Freiburg, 79106, Germany
  • Berufsgenossenschaftliche Kliniken Bergmannstrost
    Halle (Saale), 06112, Germany
  • Universitätsklinik Hamburg Eppendorf
    Hamburg, 20246, Germany
  • Universität Heidelberg
    Heidelberg, 69120, Germany
  • Friedrich-Schiller-Universitätsklinikum
    Jena, 07747, Germany
  • Universitätsklinikum Leipzig
    Leipzig, 04103, Germany
  • Klinikum der Stadt Ludwigshafen
    Ludwigshafen, 67063, Germany
  • Philipps-Universität Marburg
    Marburg, 35039, Germany
  • Technische Universität München Klinikum rechts der Isar
    München, 81675, Germany
  • Universitätsklinikum Münster
    Münster, 48149, Germany
  • Klinikum Osnabrück GmbH
    Osnabrück, 49076, Germany
  • Asklepios Fachklinikum Teupitz
    Teupitz, 15755, Germany
  • Neurologische Klinik, Eberhard-Karls-Universität Tübingen
    Tübingen, 72076, Germany
  • Universitätsklinikum Ulm
    Ulm, 89081, Germany
  • Klinika Neurologii z Pododdziałem Udarowym
    Białystok, 15-276, Poland
  • Wojewódzki Szpital Specjalistyczny im. Mikołaja Kopernika w Gdańsku, Oddział Neurologiczny i Leczenia Udarów Mózgu
    Gdańsk, 80-803, Poland
  • II Klinika Neurologii
    Warszawa, 02-957, Poland
  • Instytut Psychiatrii i Neurologii, I Klinika neurologii
    Warszawa, 02-957, Poland
  • Uniwersytecki Szpital Kliniczny im. Wojskowej Akademii Medycznej Uniwersytetu Medycznego w Łodzi, Centralny Szpital Weteranów, Klinika neurologii i epileptologii z oddziałem udarowym
    Łódź, 90-549, Poland
  • Comenius University Bratislava
    Bratislava, 813 69, Slovakia
  • 4. Faculty Hospital with Policlinic
    Bratislava, 826 06, Slovakia
  • Faculty Hospital L. Derer
    Bratislava, 833 05, Slovakia
  • Faculty Hospital
    Košice, 041 66, Slovakia
  • Faculty Hospital
    Martin, 036 59, Slovakia
  • Faculty Hospital Nitra
    Nitra, 949 01, Slovakia
  • Fakultna nemocnica Trnava
    Trnava, 917 75, Slovakia
  • Hospital Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital Clínic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Dr. Josep Trueta
    Girona, 17017, Spain
  • Hospital de la Princesa
    Madrid, 28006, Spain
  • Hospital Ramon y Cajal / Fundacion para le Investigacion Biomedica del Hospital Ramon y Cajal
    Madrid, 28034, Spain
  • Hopsital Univ. La Paz / Fundacion para la Investigacion
    Madrid, 28046, Spain
  • Hospital Univ. Virgen del Rocio
    Sevilla, 41013, Spain
  • Hospital Clínico Universitario
    Valencia, 46010, Spain
08

References and documents

Publications

  • Scheldeman L, Wouters A, Dupont P, Christensen S, Boutitie F, Cheng B, Ebinger M, Endres M, Fiebach JB, Gerloff C, Muir KW, Nighoghossian N, Pedraza S, Simonsen CZ, Ringelstein EB, Chamorro A, Grond M, Laage R, Schneider A, Thomalla G, Thijs V, Lemmens R. Reversible Edema in the Penumbra Correlates With Severity of Hypoperfusion. Stroke. 2021 Jul;52(7):2338-2346. doi: 10.1161/STROKEAHA.120.033071. Epub 2021 May 13. PubMed 33980046 ↗
  • Bu N, Khlif MS, Lemmens R, Wouters A, Fiebach JB, Chamorro A, Ringelstein EB, Norrving B, Laage R, Grond M, Wilms G, Brodtmann A, Thijs V. Imaging Markers of Brain Frailty and Outcome in Patients With Acute Ischemic Stroke. Stroke. 2021 Mar;52(3):1004-1011. doi: 10.1161/STROKEAHA.120.029841. Epub 2021 Jan 28. PubMed 33504185 ↗
  • Kufner A, Wouters A, Bracoud L, Laage R, Schneider A, Schabitz WR, Hermier M, Thijs V, Fiebach JB; AXIS2 investigators. Infarct volume-based subgroup selection in acute ischemic stroke trials. Stroke. 2015 May;46(5):1368-70. doi: 10.1161/STROKEAHA.114.008115. Epub 2015 Mar 12. PubMed 25765724 ↗
  • Ringelstein EB, Thijs V, Norrving B, Chamorro A, Aichner F, Grond M, Saver J, Laage R, Schneider A, Rathgeb F, Vogt G, Charisse G, Fiebach JB, Schwab S, Schabitz WR, Kollmar R, Fisher M, Brozman M, Skoloudik D, Gruber F, Serena Leal J, Veltkamp R, Kohrmann M, Berrouschot J; AXIS 2 Investigators. Granulocyte colony-stimulating factor in patients with acute ischemic stroke: results of the AX200 for Ischemic Stroke trial. Stroke. 2013 Oct;44(10):2681-7. doi: 10.1161/STROKEAHA.113.001531. Epub 2013 Aug 20. PubMed 23963331 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2009, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2009
First posted
Jun 25, 2009
Start
May 2009
Primary completionActual
Nov 2011
CompletionActual
Nov 2011
Last update
Dec 13, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 13, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00927836
Lead sponsor
Sygnis Bioscience GmbH & Co KG
Responsible party
Sponsor
First posted
Jun 25, 2009
Start date
May 2009
Primary completion
Nov 2011
Completion
Nov 2011
Last update
Dec 13, 2011

Study contacts

Frank Rathgeb, Dr.
study chair · Sygnis Bioscience GmbH & Co KG
Rico Laage, Dr.
study director · Sygnis Bioscience GmbH & Co KG

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Filgrastim

Start the discussion